eyenovia-logo 3

News Releases

News Releases

05/14/19

NEW YORK , May 14, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the first quarter ended
05/06/19

Presented Positive Results from Two Phase 3 MicroStat (phenylephrine 2.5% / tropicamide 1% fixed combination ophthalmic solution) Trials NEW YORK , May 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose
05/01/19

NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results
03/27/19

NEW YORK , March 27, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced its financial results for the fourth quarter and
03/13/19

NEW YORK , March 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the Company will release financial results
03/04/19

NEW YORK , March 04, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that members of management will be participating
02/25/19

MIST-2 study meets primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, good tolerability in confirmatory MIST-2 Study NEW YORK , Feb. 25, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company
02/13/19

Expanded, more efficient development aimed at maximizing MicroProst's program value NEW YORK , Feb. 13, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print
02/06/19

On track to initiate Phase III trial in H1 2019 NEW YORK , Feb. 06, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced
01/30/19

MIST-1 study met primary endpoint First-in-class fixed combination mydriatic agent demonstrated robust efficacy, high tolerability; Study further validates OpteJetâ„¢ platform delivery technology Company to host conference call at 8:30 AM ET on January 30, 2019 NEW YORK , Jan.

Contact us for more information

Contact us today to learn more about how our microdosing technology is poised to transform
the standard of care in ophthalmic therapeutic delivery.

295 Madison Ave., Suite 2400, New York, NY 10017     +1 (917) 289-1117

[email protected]